Repligen Corporation (NASDAQ:RGEN) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.28 per share.
For the full year, analysts predict revenues of $ 337.53 million, while looking forward to income of $ 1.28 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 332.00 million ~ $ 340.00 million, where as bottomline are predicted in a range of $ 1.24 ~ $ 1.29 per share
Click Here For More Historical Outlooks Of Repligen Corporation
Previous Quarter Performance
Repligen Corporation recorded income for the second quarter of $ 0.42 per share, from the revenue of $ 87.50 million. The consensus estimates are income of $ 0.27 per share from $ 78.38 million in revenue. The bottom line results beat street analysts by $ 0.15 or 55.56 percent, at the same time, top line results outshined analysts by $ 9.12 million or 11.64 percent.
Stock Performance
Shares of Repligen Corporation traded up $ 8.86 or 4.98 percent on Wednesday, reaching $ 186.87 with volume of 583.90 thousand shares. Repligen Corporation has traded high as $ 189.67 and has cracked $ 180.95 on the downward trend
The closing price of $ 186.87, representing a 127.02 % increase from the 52 week low of $ 78.41 and a 6.15 % decrease over the 52 week high of $ 189.67.
The company has a market capital of $ 9.81 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Repligen Corporation will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.repligen.com
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes.
